Seattle-based Neoleukin folded into New York biotech after merger

Neoleukin Therapeutics, a biotech company that spun out of the University of Washington in 2019, finalized its merger with Neurogene, a biotech firm based in New York on December 19.

Neurogene will pass its name down to the newly merged company and will assume management responsibilities, along with 84% of company shares. Along with the merger, Neurogene also announced an influx of $95 million in private funding.

The combined company will prioritize Neurogene’s mission of developing a treatment pipeline for neurological disease.

READ THE STORY at Puget Sound Business Journal »